{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:19Z","timestamp":1790352559687,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.esmoop.2025.105931","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:26:09Z","timestamp":1767846369000},"page":"105931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact and effective management of nausea\/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"K.","family":"Shitara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4667-1817","authenticated-orcid":false,"given":"E.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-9339","authenticated-orcid":false,"given":"F.","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pophale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Matney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Matsangou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gourgioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ranganath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4062-0808","authenticated-orcid":false,"given":"S.J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.105931_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105931_bib2","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","article-title":"claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing","volume":"21","author":"Niimi","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105931_bib3","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105931_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","article-title":"A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer","volume":"100","author":"Sahin","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105931_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol"},{"issue":"10389","key":"10.1016\/j.esmoop.2025.105931_bib6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105931_bib7","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105931_bib8","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJMc2409512","article-title":"Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma","volume":"391","author":"Shitara","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2025.105931_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2024.42.3_suppl.372","volume":"42","author":"Shitara","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105931_bib10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"issue":"10294","key":"10.1016\/j.esmoop.2025.105931_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105931_bib12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10302","key":"10.1016\/j.esmoop.2025.105931_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"9742","key":"10.1016\/j.esmoop.2025.105931_bib14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.105931_bib15","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.esmoop.2025.105931_bib16","article-title":"Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND\/UCLA modified Delphi panel study","volume":"7","author":"Klempner","year":"2025","journal-title":"ESMO Gastrointestinal Oncol"},{"key":"10.1016\/j.esmoop.2025.105931_bib17","series-title":"VYLOY\u00ae (zolbetuximab-clzb)","year":"2024"},{"key":"10.1016\/j.esmoop.2025.105931_bib19","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Antiemesis V.2.2025","year":"2025"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105931_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)","volume":"26","year":"2023","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105931_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105931_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jphs.2024.08.005","article-title":"Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets","volume":"156","author":"Kinugasa","year":"2024","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.esmoop.2025.105931_bib23","article-title":"Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice","volume":"7","author":"Shimozaki","year":"2025","journal-title":"ESMO Gastrointestinal Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105931_bib24","article-title":"Trial in progress: phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101)","volume":"40","author":"Smyth","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925018010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925018010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:26:12Z","timestamp":1773966372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925018010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2059702925018010"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105931","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact and effective management of nausea\/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105931"}}